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Polyenes and azoles have potentially deleterious drug interactions
that can lead to important renal and hepatic toxicities in HCT recip-
ients. The echinocandins may offer safety advantages in such pa-
tients. In this analysis using data from 8 clinical development
studies, we examined renal and hepatic parameters in 588 neutro-
penic patients who received micafungin for prophylaxis of fungal in-
fections (n5 375), treatment for invasive candidiasis/candidemia
(IC/C; n5 120), or treatment for invasive aspergillosis (IA,
n5 93). The renal and hepatic function laboratory parameters for
the 3 indications are shown in Table 1; changes in laboratory param-
eters were calculated for each indication and, for the prophylaxis pa-
tients, for type of HCT. The proportion of patients with an increase
in creatinine from\2*ULN at baseline to$2*ULN at EOT and an
increase in bilirubin and ALT\2.5*ULN at baseline to$2.5*ULN
were provided by indication. Overall, the changes in hepatic and re-
nal function laboratory parameters were consistent with the underly-
ing conditions of the patients, and HCT patients did not appear to
experience greater increases in levels of creatinine, bilirubin, and
ALT compared to patients in the other groups.Description of laboratory parameters in micafungin neutropenic pa
Parameter
All patients
(n5 588)
All prophylaxis
patients
(n5 375)
Proph
non
pat
(n5
Days of micafungin, median 17.5 18.0 6.0
Creatinine (mg/dl),
median (min-max)
Baseline 0.70 (0.1-6.6) 0.6 (0.1-5.4) 0.40 (
Peak 0.86 (0.3-2.2) 0.70 (0.1-4.4) 0.70 (
EOT 0.71 (0.1-6.9) 0.70 (0.1-4.4) 0.40 (
Increase from\2 ULN at
baseline to $2 ULN at EOT, n/N (%)
16/527 (3.0) 1/363 (0.3) —
Bilirubin (mg/dl),
median, (min-max)
Baseline 0.80 (0-17.2) 0.70 (0.0-7.3) 0.80 (
Peak 1.10 (0.2-23.5) 1.10 (0.4-23.5) 0.80 (
EOT 0.80 (0.1-37.9) 0.70 (0.1-31.3) 0.60 (
Increase from\2.5 ULN at
baseline to $2.5 ULN at
EOT, n/N (%)
39/490 (8.0) 17/355 (4.8) —
ALT (U/L), median, (min-max)
Baseline 27.0 (2-655) 26.5 (4-472) 30.0 (
Peak 30.0 (1-2151) 39.0 (7-389) 44.0 (
EOT 25.0 (1-2793) 24.0 (1-2793) 27.0 (
Increase from\2.5 ULN
at baseline to $2.5 ULN
at EOT, n/N (%)
35/455 (7.7) 17/315 (5.4) —
ALT5Alanine aminotransferase; EOT5end of treatment; IA5 invasive aspe
normal.
*Comprised of 89 non-HCT patients, 16 autologous HCT patients, and 5 alloge
not available for these subgroups.
†Comprised of 57 non-HCT patients, 5 autologous HCT patients, and 31 alloge
not available for these subgroups.300
SUCCESS WITH A SHORTER COURSE PREEMPTIVE TREATMENT FOR CY-
TOMEGALOVIRUS (CMV) REACTIVATION AFTER MYELOABLATIVE HLA
MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
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The optimal duration of preemptive treatment of CMV reactiva-
tion following HCT is unclear. We analyzed 355 evaluable patients
(pts) who underwent myeloablative HCT from an HLA matched
sibling donor at Stanford University Medical Center between 1996
and 2008. Either donor or recipient was seropositive for CMV at
the time of transplant for 287 (79%) pts. Median follow up time
was 3.8 years (0.3-10.4). Patients were screened weekly for reactiva-
tion in plasma using a qualitative (1996-2000) or quantitative PCR
CMV test (2001-2008) (Amplicor, Roche Molecular Diagnostics)
through day 100 post-HCT. CMV viremia was detected in 127
(44%) of the 287 pts. Any positive result prompted pre-emptive
treatment with ganciclovir at 5 mg/kg IV twice daily for two weeks
and a concurrent investigation for signs or symptoms suggestive of
CMV disease. For patients without evidence of CMV disease in
whom CMV viremia resolved during the first three weeks, ganciclo-
vir was administered at 5 mg/kg daily for an additional week. In pa-
tients with CMV disease or in whom viremia persisted, daily
ganciclovir was administered for an additional 4 weeks. There
were no substantial differences between groups with respect to sex,
age, race, or underlying disease. The relative paucity of CMV reac-
tivation in the D+/R– group is predicted by previously published ob-
servations. Pts who successfully resolved CMV viremia with the
administration of only 3 weeks of ganciclovir were less likely (1) to
have received a preparative regimen containing TBI, (2) more likely
to have a lower initial CMV load as compared with patients whomet
criteria for 6week treatment. However, no difference between the
groups was noted regarding GVHD or treatment with steroids at
the time of initial viremia. Our data supports the utility of a 3tients
ylaxis,
-HCT
ients
30)
Prophylaxis,
autologous
HCT patients
(n5 161)
Prophylaxis,
allogeneic
HCT patients
(n5 184)
IC/Candidemia
patients
(n5 120)*
IA patients
(n5 93)†
17.0 21.0 14.0 29.0
0.2-0.9) 0.70 (0.1-5.4) 0.60 (0.1-2.7) 0.98 (0.1-4.7) 0.90 (0.2-6.6)
0.7-0.7) 0.75 (0.5-0.8) 0.70 (0.2-2.3) 0.98 (0.1-4.7) 1.00 (0.2-3.8)
0.2-0.8) 0.70 (0.2-4.4) 0.70 (0.1-2.4) 0.91 (0.1-6.9) 1.00 (0.2-3.8)
— — 10/79 (12.7) 5/85 (5.9)
0.1-2.8) 0.60 (0-3.1) 0.70 (0.1-7.3) 1.20 (0.2-11.6) 1.10 (0.1-17.2)
0.1-2.8) 1.25 (0.5-4.4) 1.10 (0.4-23.5) 1.32 (0.1-9.3) 1.30 (0.1-37.9)
0.1-5.7) 0.60 (0.1-4.4) 0.90 (0.2-31.3) 1.17 (0.2-13.9) 1.30 (0.1-37.9)
— — 9/65 (13.8) 13/70(18.6)
13-129) 23.0 (4-370) 28.0 (4-472) 31.5 (7-204) 27.0 (2-655)
13-96) 26.0 (13-33) 46.0 (7-389) 57.0 (17-88) 34.0 (3-194)
8-167) 20.0 (4-383) 28.0 (1-2793) 30.0 (6-1119) 26.0 (3-313)
— — 8/68 (11.8) 10/72 (13.9)
rgillosis; IC/C5 invasive candidiasis/candidemia; ULN5 upper limits of
neic HCT patients. Renal and hepatic function laboratory parameter data
neic HCT patients. Renal and hepatic function laboratory parameter data
